SCHEMBL7757749

SCHEMBL7757749

COC(=O)c1cccc(/C=C2\CCC3(c4cc5c(cc4C)C(C)(C)CCC5(C)C)CC23)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.38
CYP3A4 P08684 3/20 0.37
P4HB P07237 3/20 0.37
RXRA P19793 9/20 0.35
RXRB P28702 5/20 0.35
RXRG P48443 5/20 0.35
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35
RARA P10276 3/20 0.34
RARB P10826 3/20 0.34
RARG P13631 3/20 0.34
CYP26A1 O43174 2/20 0.33
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7757751 1.00 TDP1 (0.38) TDP1CYP3A4P4HBRXRARXRB
SCHEMBL7755839 0.91 RARA (0.37) RXRARXRBRXRGRARARARB
SCHEMBL7755835 0.91 RARA (0.37) RXRARXRBRXRGRARARARB
SCHEMBL7781817 0.89 RXRA (0.44) CYP3A4RXRARXRBRXRGRARA
SCHEMBL7781815 0.89 RXRA (0.44) CYP3A4RXRARXRBRXRGRARA
SCHEMBL7755028 0.80 RARB (0.53) CYP3A4RXRARXRBRXRGRARA
SCHEMBL7755022 0.80 RARB (0.53) CYP3A4RXRARXRBRXRGRARA
SCHEMBL7755067 0.74 RXRA (0.47) RXRARXRBRXRGRARARARB
SCHEMBL7755074 0.74 RXRA (0.47) RXRARXRBRXRGRARARARB
SCHEMBL7755311 0.73 RXRA (0.57) RXRARXRBRXRGRARARARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010037025-A1 New compounds, their preparation and use MURRAY ANTHONY (DK) 2001-11-01 US disclosed
EP-1077919-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP disclosed
WO-1999058486-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010037025-A1 New compounds, their preparation and use GPR119, SLC5A1, SLC5A2 TDP1 3474/4885CYP3A4 436/4885P4HB 3659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.